

# Advisory Committee on Immunization Practices (ACIP): Mumps Work Group

Kelly L. Moore MD, MPH  
Director, Tennessee Immunization Program  
Chair, Mumps ACIP Work Group

ACIP Meeting  
June 20, 2018

# Mumps Work Group: Terms of Reference

## Objective

- Evaluate and propose policy options to prevent or control mumps outbreaks in the United States

## Activities

- Review epidemiology of mumps in the 2-dose vaccine era, including the international experience
- Review available evidence on duration of immunity for mumps after 2 doses of MMR and other risk factors for vaccine failure
- Review available evidence on impact of a 3<sup>rd</sup> dose of MMR vaccine for mumps outbreak control
- Evaluate programmatic implications and cost of various policy options for a 3<sup>rd</sup> dose of MMR vaccine to prevent or control mumps outbreaks

# Mumps Work Group: Members

## ACIP

Kelly Moore, Chair  
Paul Hunter  
Cynthia Pellegrini  
Jose Romero

## Consultants

Huong McLean  
Patricia Quinlisk  
Jane Seward  
Stanley Plotkin\*

## Ex Officio Members & Liaison Representatives

Carol Baker (IDSA)  
Chas DeBolt (CSTE)  
Shalini Desai (NACI)  
Susan Even (ACHA)  
Amy Groom (IHS)  
Melissa Martinez (AAFP)  
Dawn Nolt (AAP/COID)  
Steven Rubin (FDA/CBER)  
Jane Zucker (AIM)

## CDC

Mona Marin, CDC lead  
Tracy Ayers  
Nakia Clemmons  
Carole Hickman  
Manisha Patel  
Paul Rota  
Janell Routh  
Melinda Wharton  
Patricia Wodi  
Fangjun Zhou  
Adria Lee  
Mariel Marlow

\*expert consultant on scientific discussions

# Mumps Work Group: Activities and Outcomes, February 2017-June 2018

Timeline	Activities	Outcome
<p>March-October 2017</p> <ul style="list-style-type: none"> <li>• 13 WG calls</li> <li>• 4 online surveys</li> </ul>	<p>Evidence assessment</p> <ul style="list-style-type: none"> <li>• Mumps epidemiology</li> <li>• 2-dose MMR vaccine impact</li> <li>• Data on and experience with 3<sup>rd</sup> dose MMR vaccine use</li> <li>• Critical review of published and unpublished data regarding mumps outbreaks</li> </ul>	<p>October 2017</p> <ul style="list-style-type: none"> <li>• Proposed WG recommendations</li> <li>• ACIP recommended use of a 3<sup>rd</sup> dose of mumps-virus containing vaccine for persons in the groups identified at increased risk for mumps during an outbreak</li> </ul>
<p>January-June 2018</p> <ul style="list-style-type: none"> <li>• 4 WG calls</li> <li>• 1 online survey</li> <li>• 3 rounds of document review</li> </ul>	<p>Technical consultation, discussion and feedback for the CDC guidance for use of a 3<sup>rd</sup> dose of MMR vaccine during mumps outbreaks</p>	<p>June 2018</p> <ul style="list-style-type: none"> <li>• Proposed CDC guidance for use of a 3<sup>rd</sup> dose of MMR vaccine during mumps outbreaks presented to ACIP</li> </ul>

# Mumps Work Group: Next Steps

- Mumps ACIP WG accomplished its terms of reference
- Hiatus of WG activities
  - CDC will continue to monitor mumps epidemiology in the US and new scientific evidence that can inform better control of mumps
    - WG calls as needed as new information becomes available